Generic Prilosec
This article was originally published in The Tan Sheet
Executive Summary
Genpharm will receive up to 15% of Andrx' profits from generic omeprazole under agreement settling a dispute over which firm was first to file an ANDA for AstraZeneca's Rx proton pump inhibitor. Andrx will market generic omeprazole either under its own or Genpharm's application, depending on which more quickly can be brought to market. Omeprazole loses exclusivity in October 2001 assuming AstraZeneca receives six months of pediatric exclusivity. AstraZeneca/Procter & Gamble's NDA to switch Prilosec OTC was the subject of an Oct. 20 NDAC meeting (1"The Tan Sheet" Oct. 23, 2000, p. 3)
You may also be interested in...
Prilosec GERD Indication OTC Appropriateness Debated At NDAC Meeting
Gastroesophageal reflux disease is appropriate for OTC treatment, but AstraZeneca/Procter & Gamble's NDA to switch Prilosec OTC is not approvable, FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees decided at a joint meeting in Gaithersburg, Md. Oct. 20.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands